SUBSCRIBERS
Samsung Bioepis partners Takeda to develop original biotech drugs
Add BT as a preferred sourcePublished Mon, Aug 21, 2017 · 09:50 PM
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Seoul
SAMSUNG Bioepis Co Ltd said on Monday that it will fund and develop multiple original drugs in partnership with Japan's Takeda Pharmaceutical Co Ltd, expanding its business scope beyond copies of existing biologic drugs.
Original biotech drugs represent a business ramp-up for Samsung Bioepis, which has so far invested US$1.3 billion in drug development since being founded in 2012 and has received approvals for two biosimilar drugs in Europe and one in the United States.
Share with us your feedback on BT's products and services
